No Data
No Data
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $1
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Cuts Target Price to $1
Cellectar Biosciences Price Target Lowered to $1 From $7 at Maxim
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut